← All trials
NCT00670254
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- Aug 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Humboldt UniversityLead sponsor
- University of LeipzigStudy director
- Sepsis FoundationCollaborator
- German Federal Ministry of Education and ResearchCollaborator
- University of LeipzigCollaborator
- Humboldt UniversityReponsible party - principal investigator
- Friedrich Schiller UniversityOverall official - principal investigator
- Friedrich Schiller UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.